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Abstract
The gut microbiota exerts a role in type 2 diabetes (T2D), and deviations from a mutualistic ecosystem layout are considered a key
environmental factor contributing to the disease. Thus, the possibility of improving metabolic control in T2D by correcting gut microbiome
dysbioses through diet has been evaluated. Here, we explore the potential of two different energy-restricted dietary approaches – the
fibre-rich macrobiotic Ma-Pi 2 diet or a control diet recommended by Italian professional societies for T2D treatment – to correct gut
microbiota dysbioses in T2D patients. In a previous 21-d open-label MADIAB trial, fifty-six overweight T2D patients were randomised to the
Ma-Pi 2 or the control diet. For the present study, stools were collected before and after intervention from a subset of forty MADIAB
participants, allowing us to characterise the gut microbiota by 16S rRNA sequencing and imputed metagenomics. To highlight microbiota
dysbioses in T2D, the gut microbiota of thirteen normal-weight healthy controls were characterised. According to our findings, both diets were
effective in modulating gut microbiome dysbioses in T2D, resulting in an increase of the ecosystem diversity and supporting the recovery of
a balanced community of health-promoting SCFA producers, such as Faecalibacterium, Roseburia, Lachnospira, Bacteroides and
Akkermansia. The Ma-Pi 2 diet, but not the control diet, was also effective in counteracting the increase of possible pro-inflammatory groups,
such as Collinsella and Streptococcus, in the gut ecosystem, showing the potential to reverse pro-inflammatory dysbioses in T2D, and possibly
explaining the greater efficacy in improving the metabolic control.
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Type 2 diabetes (T2D) is markedly increasing its prevalence in
Westernised countries(1), and it represents a challenging problem
for national healthcare systems(2). Recent insights provided
evidence of an altered gut microbiota (GM) in T2D subjects,
suggesting a possible role for gut micro-organisms in the disease
onset(3–7).
Intestinal micro-organisms, and their metabolic products,
have been shown to exert relevant functions in regulating host
metabolic pathways(8). Indeed, GM components can modulate
different factors contributing to the host metabolic phenotype,
such as intestinal gluconeogenesis, insulin sensitivity, lipid
accumulation and glucose control(9,10). Although a mutualistic
GM composition is crucial to support the host energy
homeostasis, certain GM dysbioses can result in profound
deregulations of the host metabolism, supporting the onset
and consolidation of metabolic diseases, such as T2D(11,12).
Moreover, a pro-inflammatory layout of the gut microbial
ecosystem has been suggested to be the basis of chronic
inflammatory processes observed in T2D, and the new concept
of metabolic infection has been proposed(13,14). As a result
of an increased gut permeability, endotoxins from pro-
inflammatory GM components can penetrate the epithelial
barrier and aggravate metabolic inflammation and insulin
resistance in T2D(15). Thus, the GM has the potential to exert
a multifactorial role in T2D, and deviations from a health-
promoting GM composition could represent a key determinant
contributing to the disease onset(11,16–18). As diet has been
recognised as a potent modulator of the composition and
metabolism of the human GM(19), the possibility to improve
metabolic control in T2D by developing selective diets
Abbreviations: CTR, control diet; FBG, fasting blood glucose; GM, gut microbiota; KO, KEGG Orthology; PCoA, principal coordinates analysis; T2D, type 2 diabetes.
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that are able to correct the GM dysbioses has been
considered(11,16,20).
Very recently, the Ma-Pi 2 macrobiotic diet has been reported to
be more effective than a control (CTR) diet, which is based on the
dietary guidelines recommended by professional societies in Italy,
for the improvement of metabolic control in T2D patients(21).
Conceived by Mario Pianesi, the Ma-Pi 2 diet is a fibre-rich
macrobiotic diet with a prebiotic potential, which is in line with
the dietary recommendations of the Academy of Nutrition and
Dietetics(22). Specifically, the Ma-Pi 2 diet is enriched in complex
carbohydrates, legumes, fermented products, sea salt and green tea,
and it excludes fat and protein from animal source and added
sugars. In a 21-d controlled open-label trial (MADIAB trial), fifty-six
overweight T2D patients were randomised (1:1 ratio) to the Ma-Pi 2
macrobiotic diet or the CTR diet. At the end of this short-term
nutritional intervention, the Ma-Pi 2 macrobiotic diet proved to be
more effective in reducing fasting and postprandial blood glucose,
glycated Hb (HbA1c), serum cholesterol, homeostasis model
assessment of insulin resistance (HOMA-IR), BMI and waist and hip
circumferences compared with the CTR diet(21). According to the
authors, the greater effect of the high-fibre Ma-Pi 2 diet on several
metabolic parameters of T2D patients was probably because of, at
least in part, an inherent capability of favouring the recovery of a
mutualistic GM layout. To verify this hypothesis, in this study, we
specifically compared the efficacy of the Ma-Pi 2 and the CTR diet in
modulating GM dysbioses in a subset of forty overweight T2D
patients participating in the MADIAB trial, for whom stools were
successfully collected before and after intervention. To this aim,
stools were analysed for the microbiota composition by next-
generation sequencing (NGS) of the 16S rRNA gene and imputed
metagenomics. To provide a picture of the baseline GM dysbioses
in the enrolled T2D patients, their microbiota profiles were
compared with those of thirteen normal-weight healthy controls.
Our findings suggest that the Ma-Pi 2 diet has the potential to
reverse compositional and functional GM dysbioses in T2D,
favouring the recovery of a mutualistic configuration capable of
supporting the host energy homeostasis.
Methods
Study design
The design of the MADIAB trial is described in Soare et al.(21).
Briefly, it was designed as a 21-d controlled open-label trial, in
which the participants were assigned (1:1) to the Ma-Pi 2
macrobiotic diet or a CTR diet based on the dietary guidelines
for T2D recommended by professional societies in Italy. The
trial was conducted in accordance with the Declaration of
Helsinki and the Good Clinical Practice guidelines, and the
study was approved by the Institutional Review Board of
University Campus Bio-Medico (trial registration number
ISRCTN10467793; http://www.isrctn.com/ISRCTN10467793).
Written informed consent was obtained from all subjects/
patients. The Department of Endocrinology and Diabetes
of the University Campus Bio-Medico in Rome (Italy) recruited
overweight or obese (BMI 27–45 kg/m2) subjects, aged
40–77 years and affected by T2D (Table 1). Associated
metabolic syndrome was evaluated according to the National
Cholesterol Education Program Adult Treatment Panel III
criteria, although it was not an inclusion criterion. Inclusion
criteria were as follows: T2D diagnosed at least 1 year before
the start of the trial, treated exclusively with dietary interven-
tion, oral hypoglycaemic drugs or both for 6 months before
study entry. Exclusion criteria were as follows: the use of insulin
either at present or at any time in the 2 year before the study,
current use of corticosteroid therapy or any other drug that can
interfere with carbohydrate metabolism, alcohol abuse and
pregnancy. Subjects who already followed a macrobiotic
diet were excluded from the study. Participants’ eating habits
concerning the period antecedent the study start were assessed
using qualitative and quantitative questionnaires (online
Supplementary Table S1). Eligible T2D subjects were divided
into two groups according to the diet randomly assigned
(twenty-eight participants were randomised to the Ma-Pi 2
diet and twenty-eight to the CTR diet), and they were
accommodated in two different hotels, which were located
close to each other. Randomisation was stratified by BMI at
baseline and by sex.
Stratified random sampling was used to ensure that the
groups contained similar numbers of patients with BMI≥ 35·0
kg/m2 (the median in the cohort of eligible patients) and similar
number of male patients. The menus were designed as a 2-d
diet repeated cyclically along the whole duration of the study.
Both diets were energy intake restricted to 7949 kJ (1900 kcal)
for men and 7113 kJ (1700 kcal) for women (online Supple-
mentary Table S2). In particular, the CTR diet derived
energy from 40–60% carbohydrate, 10–20% protein, 30% fat
and ≥20 g/4184 kJ (1000 kcal) fibre. It was adapted to the
Mediterranean culinary style. Vegetables, fruit, cereal, fish and
white meat typical of the Mediterranean style were used;
alcohol and sucrose consumption was forbidden. Diet meal
plans and recipes are described in the Additional File 1 of the
study by Soare et al.(21). Briefly, daily diet administration was
organised in three meals (breakfast, lunch and dinner) and two
snacks, 2·5 h after breakfast and lunch. Every participant was
informed that a leftover ≥5% of the total food intake meant the
dismissal from the trial. Participants were asked to keep their
exercise habits unvaried during the intervention period,
and their physical activity was registered using a pedometer
(Tri-axial activity monitor, XL-18/XL-18 CN-AND; A&D
Medical). Primary outcomes were the change in fasting blood
glucose (FBG) and postprandial blood glucose (PPBG) levels
from the baseline (T0) to the 21st day of treatment (T1).
Secondary outcomes included changes from baseline in
plasma concentration of HbA1c, total cholesterol, LDL-
cholesterol, HDL-cholesterol and the LDL:HDL ratio, C-reactive
protein (CRP), TNF-α and IL-6, as well as insulin resistance,
body weight, BMI, waist and hip circumference and GM
composition. For GM analysis, participants were asked to
provide a faecal sample before (T0) and after the 21-d
nutritional intervention (T1). Stool samples were successfully
collected from a subset of forty T2D patients participating in the
MADIAB trial aged 50–77 years (mean age 66 years): twenty-
one assigned to the Ma-Pi 2 diet and nineteen to the CTR diet.
The gut microbiome study was conducted in this subset of forty
MADIAB participants.
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In addition, thirteen healthy controls, aged 21–40 years
(mean age 32 years) and with 18·3–24·6 kg/m2 BMI, were
enrolled for the study (Table 1). They were asked to provide
a faecal sample, and their eating habits were assessed using
qualitative and quantitative questionnaires as well (online
Supplementary Table S1). All samples were immediately frozen
at −20°C, and then transferred within 1 week to −80°C and
stored there until processing.
16S ribosomal DNA sequencing and processing
Total microbial DNA was extracted from faeces using the
DNeasy Blood & Tissue Kit (Qiagen) by introducing three
FastPrep (MP Biomedicals) bead-beating 1-min steps at
5·5 movements/s, with 5-min incubation in ice between treat-
ments(23). DNA recovery was evaluated using the NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies) and 2200
Table 1. Anthropometric characteristics of type 2 diabetes (T2D) patients, measured at T0 and T1 (after 21-d Ma-Pi 2 or control diet (CTR) intervention),
and normal-weight healthy controls




















1 Ma-Pi 2 50 F 99·1 88·4 17·5 93·5 82·8 16·5 41·4 34·3 6·5 39·1 32·2 6·1
2 Ma-Pi 2 72 M 108·6 103·2 34·1 32·4
3 Ma-Pi 2 77 F 72·8 68·7 35 33
4 Ma-Pi 2 67 M 88 82·5 30 28·2
5 Ma-Pi 2 72 F 104 96·4 50·7 47
6 Ma-Pi 2 62 M 72·4 68·6 24·3 23
7 Ma-Pi 2 76 M 130 121·7 45·5 42·6
8 Ma-Pi 2 63 F 108·4 100·5 43·2 40·1
9 Ma-Pi 2 59 M 95·7 89·1 35·4 33
10 Ma-Pi 2 75 F 73·9 70 33·2 31·5
11 Ma-Pi 2 75 F 60·1 55·2 28·9 26·5
12 Ma-Pi 2 73 M 88·9 82·9 30·7 28·7
13 Ma-Pi 2 70 F 75·8 71·5 31·3 29·5
14 Ma-Pi 2 71 F 81·1 77·2 30·9 29·5
15 Ma-Pi 2 62 M 74·7 69·2 29·6 27·4
16 Ma-Pi 2 57 F 116·9 109·3 36·8 34·4
17 Ma-Pi 2 60 M 81 75·2 27·7 25·6
18 Ma-Pi 2 76 M 77·6 72 29·9 27·7
19 Ma-Pi 2 61 F 75·6 69·9 31·3 29
20 Ma-Pi 2 72 F 77·7 73·3 31·1 29·3
21 Ma-Pi 2 66 F 93·4 88·8 40 38
1 CTR 60 F 122·2 88·2 15·5 119 85·5 14·9 50·7 32·1 6·3 49·3 31·1 6·1
2 CTR 56 M 103·1 98·6 36·5 34·9
3 CTR 51 M 88·3 85·9 33·7 32·8
4 CTR 57 F 88 85·9 33·1 32·3
5 CTR 72 F 55·9 55·3 22 22
6 CTR 73 F 77 75·2 30·8 30·1
7 CTR 74 M 89·3 86·8 27·3 26·5
8 CTR 68 M 80·7 78·8 24·9 24·4
9 CTR 74 M 72·8 69·6 28·8 27·5
10 CTR 72 M 78·5 75·1 28·2 27
11 CTR 53 M 105·4 100·2 32·1 30·6
12 CTR 69 M 85·9 83·3 28·1 27·2
13 CTR 74 F 80·7 77·8 33·6 32·3
14 CTR 67 M 104·5 100·6 36·2 34·9
15 CTR 62 M 80·3 78·3 29·5 28·8
16 CTR 69 M 104·2 101·2 34·8 33·8
17 CTR 63 F 85·7 83·5 31·9 31·1
18 CTR 64 F 72·4 69·3 27·6 26·4
19 CTR 65 F 101·8 99·8 40·7 39·9
1 IT1 38 M 78·2 65·6 10·7 N/A N/A N/A 22·9 22·0 1·8 N/A N/A N/A
2 IT2 34 F 62·4 N/A 20 N/A
3 IT3 29 F 60·9 N/A 22·4 N/A
4 IT4 27 M 87·2 N/A 22·9 N/A
5 IT5 30 M 72·3 N/A 23·2 N/A
6 IT6 32 F 58·4 N/A 22·7 N/A
7 IT9 39 F 54·3 N/A 20·3 N/A
8 IT10 40 F 53·1 N/A 18·3 N/A
9 IT11 40 F 67·6 N/A 24·8 N/A
10 IT12 30 F 57·5 N/A 22 N/A
11 IT14 21 F 59·3 N/A 21·3 N/A
12 IT15 29 M 80·4 N/A 24·6 N/A
13 IT16 32 F 61·3 N/A 21·2 N/A
F, female; M, male; IT, Italian healthy controls.
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TapeStation instrument (Agilent Technologies). For each sample,
the V3–V4 region of the 16S rRNA gene was PCR-amplified in
25-μl volumes containing 12·5ng of microbial DNA, 2× KAPA HiFi
HotStart ReadyMix (Kapa Biosystems) and 200nmol/l of
S-D-Bact-0341-b-S-17/S-D-Bact-0785-a-A-21 primers(24) carrying
Illumina overhang adapter sequences (Bio-Fab Research). Thermal
cycle consisted of an initial denaturation at 95°C for 3min, twenty-
five cycles of denaturation at 95°C for 30 s, annealing at 55°C for
30 s, extension at 72°C for 30 s and a final extension step at 72°C for
5min. Amplicons of about 460bp were purified with a magnetic
bead-based clean-up system (Agencourt AMPure XP; Beckman
Coulter) and sequenced on Illumina MiSeq platform using a
2×300bp paired end protocol, according to the manufacturer’s
instructions (Illumina). Briefly, indexed libraries were prepared by
limited-cycle PCR using Nextera technology and further cleaned up
with AMPure XP magnetic beads (Beckman Coulter). Libraries
were pooled at equimolar concentrations, denatured and diluted to
6pmol/l before loading onto the MiSeq flow cell. Amplicon
sequences were deposited in the MG-RAST database (http://
metagenomics.anl.gov/linkin.cgi?project=17675).
Bioinformatics and statistics
Raw sequences were processed using a pipeline combining
PANDAseq (paired-end assembler for Illumina sequences)(25) and
QIIME (Quantitative Insights Into Microbial Ecology)(26). High-
quality reads were binned into operational taxonomic units (OTU)
at a 0·97 similarity threshold using UCLUST(27). Taxonomy was
assigned using the RDP (Ribosomal Database Project) classifier
against Greengenes database (May 2013 release). Chimera filtering
was performed by discarding all singleton OTU. α Rarefaction was
analysed by using the Faith’s phylogenetic diversity, Chao1,
observed species and Shannon index metrics. β Diversity was
estimated by computing weighted and unweighted UniFrac dis-
tances. Weighted UniFrac distances were used for principal coor-
dinates analysis (PCoA) and plotted by the rgl and vegan packages
of R. Data separation in the PCoA was tested using a permutation
test with pseudo F ratios (function adonis in the vegan package).
Heat-map analysis was performed using the R ggplot2 package.
Metagenome imputation of Greengenes-picked OTU was per-
formed using PICRUSt (Phylogenetic Investigation of Communities
by Reconstruction of Unobserved States)(28) with default settings.
The KEGG (Kyoto Encyclopedia of Genes and Genomes) Orthol-
ogy (KO) database(29) was used for functional annotation. Pro-
crustes superimposition was conducted on the normalised KO gene
data set and phylogenetic compositional data using vegan and rgl.
The correlation between age and GM diversity was computed
by Kendall τ correlation test. To identify which feature in
each diet contributed to the modulation of single bacterial
groups, a graphical representation of phylogenetic data and
dietary metadata was obtained using GraPhlAn(30).
All statistical analyses were performed in R, version 3.1.3.
Significant differences were assessed by Wilcoxon’s signed
rank-sum test. When appropriate, a paired test was used. Where
necessary, P values were corrected for multiple comparisons
using the Benjamini–Hochberg method. P< 0·05 was con-
sidered statistically significant.
Statistical analysis of the primary and other secondary
outcomes from the subset of forty MADIAB participants who
provided stool samples was carried out as reported by Soare
et al.(21). Briefly, quantitative variables were summarised using
percentiles, and the comparison between time points and dietary
groups was performed using the Wilcoxon’s signed rank-sum test.
Results
Comparison of the gut microbiota compositional
structure between overweight type 2 diabetes patients
and healthy controls
The phylogenetic structure of the GM ecosystem of forty
overweight T2D patients before (T0) and after (T1) nutritional
intervention, and thirteen normal-weight healthy adults,
was characterised by NGS of the V3–V4 region of the 16S
ribosomal DNA (rDNA) (online Supplementary Fig. S1).
A total of 3 198 509 high-quality reads were obtained, with
a mean of 30 277 (SD 4850) reads per sample. Reads were clus-
tered in 30 874 OTU at 97% identity. Rarefaction curves obtained
with Shannon, Chao1, PD (phylogenetic diversity) whole tree
and observed species phylogenetic metrics approximated the
saturation level after 3300 reads (online Supplementary Fig. S1).
To characterise GM dysbioses in T2D at the enrolment, the
compositional structure of the GM at T0 was compared with
that of healthy controls. In the online Supplementary Table S1,
we provide the dietary behaviours during the 6 months before
the trial for all T2D patients, as well as the dietary habits of the
healthy controls. T2D patients were characterised by a sig-
nificant reduction of the GM Shannon diversity index (P< 0·05,
Wilcoxon’s signed rank-sum test). Even if it cannot be excluded
that the age differences between T2D patients (mean age
66 years) and healthy controls (mean age 32 years) contribute,
at least in part, to the observed differences in GM diversity, we
failed to detect any significant correlation between age and
microbiome diversity in our data set (online Supplementary
Fig. S2). The PCoA of the weighted UniFrac distances resulted in
a significant segregation between the two groups (Fig. 1(a))
(P< 0·001, permutation test with pseudo F ratios), confirming
the presence of compositional differences in the GM structure
of T2D patients and healthy controls. To identify the microbial
genera responsible for this separation, the biplot of the average
bacterial coordinates weighted by the corresponding bacterial
abundance per sample was superimposed on the PCoA plot
(Fig. 1(b)), as previously carried out by Lozupone et al.(31).
The GM genera that clustered with T2D patients and healthy
controls and the corresponding relative abundance values
are reported in Table 2. According to our biplot analysis,
T2D patients showed a higher load of several potentially
pro-inflammatory GM components, such as Enterobacteriaceae,
Collinsella(32) and Streptococcus. In particular, Enterobacter-
iaceae, Collinsella and Streptococcus were, respectively, 8·5, 3·5
and 4·1 times more in T2D patients than in healthy controls.
T2D patients also showed a significantly higher abundance
of Lactobacillus, with an increase of about 150 times, and
Lachnospiraceae:Ruminococcus, which was 1·1 times more
than in healthy controls. Conversely, T2D patients were slightly
Gut microbiota and diet in type 2 diabetes 83
depleted in several health-promoting SCFA producers, such as
Bacteroides (0·7 times less), Prevotella (0·8 times less), Lachnospira
(0·7 times less), Roseburia (0·2 times less) and Faecalibacterium
(0·4 times less). Taken together, our data demonstrate the
presence of dysbioses in the GM of T2D patients, characterised by
an overall reduction of mutualistic GM components in favour of a
corresponding increase in potential pro-inflammatory groups.
Structural modulation of the gut microbiota of type 2
diabetes patients after nutritional intervention
T2D patients participating in the MADIAB trial were randomised
(1:1 ratio) to follow the Ma-Pi 2 or the CTR diet. Primary and
secondary outcomes for the fifty-one patients who completed
the trial were provided by Soare et al.(21). As stool samples for
gut microbiome characterisation were successfully collected
before and after intervention from twenty-one patients assigned
to the Ma-Pi 2 diet and nineteen patients assigned to the CTR
diet, primary and secondary outcomes were re-analysed in
this subset of forty MADIAB participants. The obtained data
confirmed a significant reduction of FBG and PPBG in both diet
groups, which was significantly higher for patients following the
Ma-Pi 2 diet compared with those following the CTR diet. With
regard to secondary outcomes, the Ma-Pi 2 diet group showed a
significantly higher reduction in HOMA-IR, total cholesterol,
LDL-cholesterol and LDL:HDL ratio compared with the CTR
group (Table 3). Furthermore, although both diets were
effective in reducing the plasma TNF-α levels, only the Ma-Pi 2
dietary intervention resulted in a significant reduction in plasma
levels of CRP and IL-6 (Table 4).
We then explored the impact of dietary interventions on the
GM ecosystem of T2D patients. To visualise the total variation in
the data set, a PCoA analysis of the weighted UniFrac distances
between the Ma-Pi 2 and CTR groups at T0 and T1 and the
healthy controls was performed (online Supplementary Fig. S3).
The PC2 axis – which accounts for 24% of the total variability –
was positively associated with T2D (P< 0·05, Wilcoxon’s signed
rank-sum test). Thus, the efficacy of dietary interventions in
redressing T2D-associated GM-dysbioses was assessed by
comparing the variation of the average (± SEM) PC2 coordinates
for each group of samples (Fig. 2). Although at T0 both Ma-Pi 2
and CTR diet groups showed significantly higher PC2 coordi-
nates compared with healthy controls (P = 0·01 and P= 0·03,
respectively), at T1 no significant difference between both diet
groups and healthy controls was observed. These data support
the potential of both dietary interventions to redress T2D-
associated GM dysbioses, favouring the recovery of a mutua-
listic ecosystem layout.
The specificity of each dietary intervention in correcting the
GM dysbioses in T2D patients was evaluated by comparing the
compositional structure of the GM ecosystem before (T0) and
after (T1) the nutritional intervention, as reported in the two
PCoA plots of weighted UniFrac distances, which also included
the responding bacterial genera and biochemical parameters
(Fig. 3). A significant segregation between the GM profiles at T0
and T1 was obtained for both interventions (P= 0·01 and
P= 0·04 for Ma-Pi 2 and CTR diet, respectively; permutation test
with pseudo F ratios), indicating that both diets were effective in
modulating the GM of T2D patients. Although both diets tended
to increase the GM Shannon diversity (P= 0·09 and P= 0·06 for
Ma-Pi 2 and CTR diet, respectively; Wilcoxon’s signed rank-sum
test), no significant difference in within-group diversity between
time points was observed (Fig. 3). Interestingly, in the case of
the Ma-Pi 2 diet, we detected significant associations between
changes in GM components and changes in biochemical
parameters (Fig. 3(a)). In particular, Faecalibacterium, which
increased at T1, showed an inverse association with FBG.
Analogously, Bacteroides and Akkermansia, both positively
responding to the Ma-Pi 2 diet, showed an inverse trend with
respect to total and LDL-cholesterol. Conversely, Lachnospir-
aceae:Ruminococcus, decreasing after the Ma-Pi 2 diet, was




































Fig. 1. Comparison of the gut microbiota compositional structure between
overweight type 2 diabetes (T2D) patients at baseline and healthy controls.
(a) Principal coordinates analysis (PCoA) based on weighted UniFrac
distances shows separation between forty overweight T2D patients at T0 and
thirteen normal-weight healthy controls. , Healthy controls; , T2D patients.
P< 0·001; permutation test with pseudo F ratios. (b) Superimposition
of microbial genera on the PCoA plot in order to identify the genera involved
in this separation. Sphere width is proportional to the mean relative abundance
of the genus across all samples. The two components explain 37·8 and 23·9%
of the variance, respectively. , , Centroids for each group with indication of
standard errors on each coordinate axis; uncl, unclassified.
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To dissect the specific GM compositional changes in
response to the dietary regimen, we focused our analysis on the
core GM community, defined as the sum of the microbial
genera present at a relative abundance >1% in at least 30% of
the subjects. Selected genera accounted together for >80% of
the total ecosystem. To estimate the degree of dysbiosis of the
core GM in T2D, the ratio of the median genus abundance in
T2D patients and healthy controls was calculated. The heat map
of the log-ratios at T0 and T1 for the Ma-Pi 2 and the CTR diet is
shown in Fig. 4. According to our findings, both diets were
effective in counteracting the decrease of Bacteroides, Dorea
and Faecalibacterium in T2D patients, as demonstrated by the
recovery of median abundance values similar to those of
healthy controls. Moreover, both Ma-Pi 2 and CTR diet resulted
in an increase of Akkermansia above the abundance values
characteristic of healthy controls. On the other hand, both diets
supported the reduction of Lachnospiraceae:Ruminococcus
down to the median abundance values shown by healthy
controls. Diet-specific effects on the GM composition of T2D
patients regarded only a few genera under-represented in T2D
patients compared with healthy controls: Lachnospira and
Roseburia, for which only the CTR diet favoured the recovery of
health-like median abundance values, and Oscillospira, for
which the recovery of health-like values occurred only in the
Ma-Pi 2 diet group. Conversely, the genera Collinsella and
Streptococcus, and unclassified Lachnospiraceae, which were
enriched in T2D patients compared with healthy controls,
decreased down to health-like abundances only in patients who
underwent the Ma-Pi 2 diet intervention.
To highlight specific dietary features affecting the GM com-
position, a comparison between the microbiota profiles at T1 of
the two groups was performed, taking into account also the
dietary features of the two different interventions (Fig. 5). T1
samples from the Ma-Pi 2 diet group showed significantly
higher abundance of Peptostreptococcaceae (P= 0·02;
Wilcoxon’s signed rank-sum test) and Leuconostocaceae
(P= 0·0002), which were also positively correlated with the
ingested amount of dietary components that were represented
in a higher percentage in Ma-Pi 2 compared with the CTR diet
(whole grain 28·1 v. 8·5%, vegetables, sauces and herbs 64·5 v.
32·0%), or only present in the Ma-Pi 2 diet (seeds, seaweeds
and fermented products) (see also online Supplementary Table
S2). On the contrary, bacteria from the family Erysipelo-
trichaceae showed significantly higher abundance in T1 sam-
ples from the CTR diet group (P= 0·008), and were positively
correlated with the ingested amount of dietary components
present only in CTR diet (bread, cereal, pasta and grains, meats,
eggs and meat broths, dairy products, fruit and fruit juice and
extra-virgin olive oil). The same positive correlations were
obtained for Coriobacteriaceae, even if the abundance of this
bacterial family was not significantly higher in the CTR diet
group T1 samples. This bacterial group also showed a positive
correlation with the food category ‘other starch’ (containing
legumes and potatoes), which was more represented in the CTR
diet than in the Ma-Pi 2 diet (5·5 v. 3·0%). This food category
was also correlated to the Ruminococcaceae family.
Impact of nutritional intervention on the functional
configuration of the gut microbiome of type 2
diabetes patients
To gain insight into the GM functions, gut metagenomes
structures were inferred from the respective phylogenetic pro-
files using PICRUSt(28), as previously performed by David
et al.(19) and Morgan et al.(33). A total of 329 KEGG pathways
were generated, of these 249 showed a significantly different
abundance between healthy controls and T2D patients, and
thirty-four showed a significant variation in response to the
Ma-Pi 2 diet, whereas no KEGG pathway responded
significantly to the CTR diet. The Procrustes analysis of the 16S
rDNA sequences and imputed KO gene data set co-illustrates
the data, supporting the significant association between
taxonomic and inferred functional profiles of the gut micro-
biome across our study cohort (P= 0·001, Protest; online
Supplementary Fig. S4). The PCoA of the imputed functional
Table 2. Relative genus abundance in forty overweight type 2 diabetes (T2D) patients and thirteen normal-weight healthy controls
(Percentages and standard deviations)*
Genera Rel. Ab. (T2D, %) SD Rel. Ab. (healthy, %) SD P
Bifidobacterium 3·32 0·05 7·23 0·05 0·007
Collinsella 2·67 0·02 0·60 0·01 0·01
Bacteroides 3·05 0·04 10·8 0·09 0·002
Streptococcus 3·62 0·07 0·73 0·01 0·09
Dorea 2·06 0·01 1·56 0·01 0·1
Lachnospira 0·47 0·01 1·55 0·01 0·0006
Roseburia 5·38 0·07 6·98 0·05 0·07
Lachnospiraceae:Ruminococcus 4·98 0·05 2·33 0·02 0·01
Faecalibacterium 4·95 0·04 7·85 0·05 0·02
Oscillospira 1·18 0·01 1·71 0·01 0·04
Unclassified Enterobacteriaceae 1·79 0·03 0·19 0·01 0·2
Prevotella 0·42 0·01 1·97 0·04 0·1
Eubacterium 1·18 0·02 0·26 0·01 0·08
Dialister 1·08 0·02 0·95 0·02 0·8
Lactobacillus 2·98 0·08 0·02 0·01 0·0002
Rel.Ab., relative abundance.
* Relative P values calculated by applying the Wilcoxon’s signed rank-sum test are also reported
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Table 3. Primary and secondary outcome comparison between Ma-Pi 2 and control (CTR) diet at T0 and T1
(Medians and 1st–3rd quartile ranges)
Ma-Pi 2 diet (n 21) CTR diet (n 19)
T0 T1 T0 T1
Median 1st–3rd quartile Median 1st–3rd quartile P* Median 1st–3rd quartile Median 1st–3rd quartile P† P‡ P§
Fasting blood glucose (mg/l) 1260 1110; 1530 950 850; 1000 0·007 1380 1125; 1645 1080 1025; 1150 0·004 0·7 0·0002
Postprandial blood glucose (mg/l) 1270 1090; 1790 1000 940; 1060 0·009 1470 1360; 2130 1275 1117; 1537 0·009 0·03 0·0002
HbA1c (%) 6·5 6·10; 7·7 6·1 5·8; 7·0 0·2 6·9 6·4; 7·5 6·8 6·2; 7·1 0·4 0·7 0·3
HOMA-IR 3·3 1·4; 4·2 1·0 0·6; 2·1 0·0004 3·2 0·9; 4·6 1·4 1·1; 2·2 0·08 0·8 0·1
Total cholesterol (mg/l) 1780 1550; 2290 1230 1030; 1390 0·0002 1830 1520; 2140 1560 1375; 1895 0·1 0·9 0·01
LDL-cholesterol (mg/l) 1020 870; 1340 630 430; 870 0·0003 1050 880; 1270 850 670; 1045 0·07 0·9 0·03
HDL-cholesterol (mg/l) 490 390; 520 440 380; 510 0·5 500 440; 570 470 405; 570 0·7 0·4 0·3
LDL:HDL ratio 2·4 2·0; 3·0 1·5 0·9; 1·9 0·004 2·0 1·9; 2·8 1·8 1·4; 2·3 0·2 0·2 0·2
Weight (kg) 81·1 75·6; 99·1 77·2 70·0; 93·5 0·2 85·9 79·4; 102·5 83·3 75·2; 92·7 0·2 0·8 0·7
BMI (kg/m2) 31·3 30·0; 36·8 29·5 28·2; 34·4 0·2 30·8 27·8; 34·2 30·1 26·9; 33·3 0·4 0·1 0·4
Waist circumference (cm) 108·1 100·3; 114·7 103·4 95·8; 11·7 0·2 105·5 101·8; 112·8 102·9 100·1; 108·0 0·4 0·6 0·9
Hip circumference (cm) 109·5 103·3; 123·8 105·3 101·8; 120·0 0·4 109·1 100·6; 117·5 107·5 99·5; 115·1 0·6 0·5 0·8
HbA1c, glycated Hb; HOMA-IR, homeostasis model assessment of insulin resistance.
* P values indicated for T0 and T1 for Ma-Pi 2 diet.
† P values indicated for T0 and T1 for CTR diet.
‡ P values indicated for Ma-Pi 2 and CTR diet at T0.
§ P values indicated for Ma-Pi 2 and CTR diet at T1.
Table 4. Inflammatory marker comparison between Ma-Pi 2 and control (CTR) diet at T0 and T1
(Medians and 1st–3rd quartile ranges)
Ma-Pi 2 diet (n 21) CTR diet (n 19)
T0 T1 T0 T1
Median 1st–3rd quartile Median 1st–3rd quartile P* Median 1st–3rd quartile Median 1st–3rd quartile P value† P value‡ P value§
CRP (mg/l) 3·2 1·2; 11·8 1·0 0·3; 2·1 0·004 2·7 1·4; 5·9 1·6 1·1; 4·9 0·4 0·8 0·03
TNF-α (pg/ml) 23·3 0·0; 35·7 0·0 0·0; 2·1 0·001 26·2 11·2; 38·9 4·0 0·5; 8·4 0·002 0·4 0·01
IL-6 (pg/ml) 4·3 0·8; 6·4 2·9 2·4; 5·1 0·006 3·3 0·1; 5·5 3·5 2·1; 5·8 0·4 0·2 0·6
CRP, C-reactive protein.
* P values indicated for T0 and T1 for Ma-Pi 2 diet.
† P values indicated for T0 and T1 for CTR diet.
‡ P values indicated for Ma-Pi 2 and CTR diet at T0.











GM profiles showing segregation among the Ma-Pi 2 and CTR
groups at T0 and T1 and healthy controls is provided as the
online Supplementary Fig. S5.
The Euclidean principal component analysis (PCA) of the KO
level gene abundances showed separate clustering between the
gut microbiome structure of T2D patients at T0 and healthy
controls (P= 0·03, permutation test with pseudo F ratios). To
identify functions responsible for this separation, the average
coordinates of the metabolic pathways in all samples, weighted
by gene count per sample, were obtained and the resulting
biplot of pathway distribution was superimposed on the PCA
plot (Fig. 6). The pathways clustering with T2D patients and
healthy controls are listed in the online Supplementary Table S3.
In the context of this functional separation, T2D patients
showed a general perturbation in microbiome pathways
involved in the metabolism of amino acids, lipids and second-
ary metabolites. In particular, T2D patients were depleted in
genes involved in the metabolism of D-arginine and D-ornithine,
as well as of D-glutamine and D-glutamate, while being enriched
in pathways involved in tyrosine metabolism and alanine,
aspartate and glutamate metabolism. This functional layout may
lead to a reduced production of arginine – as a result of both the
reduction of pathways directly involved in arginine biosynthesis
and the lower amount of glutamate available for arginine
biosynthesis – and to a corresponding increase in alanine levels.
Although arginine has been reported as insulinogenic(34), an
increased alanine production has been connected to
augmented energy intake, cholesterol level and BMI(35).
Furthermore, an increased tyrosine metabolism in T2D
patients could result in higher levels of the 4-cresol metabolite,
which has been associated with diverse inflammatory
conditions in the gut(36). Finally, compared with healthy
controls, the GM of T2D patients showed increased abundance
of functions involved in the arachidonic acid metabolism.
Interestingly, the bacterial metabolism of this key inflammatory
intermediate is a well-recognised immune-escaping strategy
for proteobacteria(37). A higher level of arachidonic acid
metabolism in the GM of T2D patients, together with the
increase in the biosynthesis of polyketide sugars – bacterial
secondary metabolites with a range of biological functions
including immunosuppression(38) – might be the result of
the hypothesised bloom of pro-inflammatory pathobionts in
the gut.
With the aim to explore the impact of nutritional interven-
tions on the functional configuration of the gut microbiome in
T2D patients, the Euclidean PCA of KO level gene abundances
at T0 and T1 for both dietary groups was carried out. Differently
from the CTR diet, which resulted in no significant functional
change in the predicted gut metagenome (P= 0·4, permutation
test with pseudo F ratios), the Ma-Pi 2 diet was effective in
modulating the GM metagenome in T2D patients, as demon-
strated by significant sample clustering according to the time
point (P= 0·007). As previously described, the corresponding
biplot of metabolic pathway distribution was superimposed on
the PCA plot (Fig. 7). The pathways clustering with the Ma-Pi 2
diet time points are listed in online Supplementary Table S3.
According to our findings, the Ma-Pi 2 diet effectively coun-
teracted the functional dysbioses in the GM of T2D patients,
resulting in the decrease of the abundance of several
T2D-associated GM functional markers, such as alanine meta-
bolism, arachidonic acid metabolism and polyketide sugar
biosynthesis, as well as in the reduction of GM functions related
to oxidative phosphorylation and glycosphingolipid biosynth-
esis. Moreover, the Ma-Pi 2 diet favoured an increase in GM
functions involved in D-glutamine and D-glutamate metabolism,
previously reported as reduced in T2D patients, and in the
biosynthesis of unsaturated fatty acids, which have been
shown to improve lipoprotein profile, glycaemic control and
antioxidant status in T2D(39,40). Finally, the Ma-Pi 2 diet resulted
in the increase of GM pathways involved in the metabolism of
taurine, cysteine, methionine, valine, leucine and isoleucine,
potentially providing the host with an additional source of
important nutrients and essential amino acids.
Discussion
In the present study, the GM phylogenetic and functional dys-
bioses in forty overweight T2D patients participating in the
MADIAB trial(21) were explored. In agreement with previous
findings(11), T2D involved a significant reduction of the GM
diversity, which is a common feature shared by several disease-
associated dysbiotic microbiome configurations, such as those
associated with inflammatory bowel disease and age(41,42).
According to our results, the reduction of the GM compositional
diversity in T2D corresponded to phylogenetic changes. T2D
patients were indeed enriched in Lactobacillus, Lachnospir-
aceae:Ruminococcus and in several potential pro-inflammatory
GM components, such as Enterobacteriaceae, Collinsella and
Streptococcus(32,39,43–46), whereas they were depleted in
important health-promoting SCFA producers, such as members
of Lachnospiraceae, Faecalibacterium, Bacteroides and Prevotella.
Strengthening these findings, analogous T2D-associated GM
structural dysbioses have already been identified in previous
studies(3,6,7,47). Subsequently, we explored the changes in
GM functions matching these compositional perturbations by
inferred metagenomics. Our data suggest deregulation in
pathways involved in the metabolism of amino acids, lipids








Fig. 2. Variation of the weighted UniFrac PC2 coordinates between the study
groups. , Ma-Pi 2 diet group at T0; , control (CTR) diet group at T0;
, healthy controls; , Ma-Pi 2 diet group at T1; , CTR diet group at T1. For
each group, average (± SEM, error bar) PC2 coordinates are shown. The
significance of the differences between the PC2 coordinates of the groups is
indicated as follows: * P< 0·001 (Ma-Pi 2 diet group at T0 v. T1), ** P= 0·01
(CTR diet group at T0 v. T1), *** P= 0·01 (Ma-Pi 2 diet group at T0 v. healthy
controls), **** P= 0·03 (CTR diet group at T0 v. healthy controls); Wilcoxon’s
signed rank-sum test.
Gut microbiota and diet in type 2 diabetes 87
reduced abundance of functions for the metabolism of D-arginine
and D-ornithine, as well as of D-glutamine and D-glutamate, a
corresponding increase in the metabolism of tyrosine, alanine,
aspartate and glutamate, and a higher load of functions involved in
arachidonic acid metabolism and polyketide sugar biosynthesis.
The observed T2D-related dysbiotic microbial community
could exert a multifactorial role in the disease onset,
contributing to metabolic and immune deregulation. Indeed,
the T2D GM is slightly depleted in fibrolytic health-promoting


































Fig. 3. Comparison of the gut microbiota compositional structure of type 2 diabetes (T2D) patients before and after the nutritional interventions. (a) Principal
coordinates analysis (PCoA) based on weighted UniFrac distances for T2D subjects following the Ma-Pi 2 diet (n 21) shows separation between T0 ( ) and T1 ( ).
The two components explain 35·0 and 24·8% of the variance, respectively. P= 0·01; permutation test with pseudo F ratios. (b) PCoA based on weighted UniFrac
distances for T2D subjects following the control (CTR) diet (n 19). , T0; , T1. The two components explain 32·0 and 20·2% of the variance, respectively. P= 0·04;
permutation test with pseudo F ratios. Lines connect T0 and T1 samples from the same patient. , responding bacterial genera and biochemical
parameters, respectively; , direction of significant correlations; , , , , centroids for each time point.
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from the degradation of indigestible plant polysaccharides and
starch, such as the butyrate-producing Dorea, Lachnospira,
Roseburia and Faecalibacterium, and the propionate-
producing Bacteroides and Prevotella(48). Even if the biologi-
cal relevance of this depletion of SCFA producers remains to be
determined, it could result in the reduction of bioavailability of
these crucial GM metabolites in the gut, with consequences on
the host metabolic and immunological homeostasis. For
instance, butyrate and propionate are important for host glu-
cose control(11), insulin sensitivity regulation, insulin signalling
and intestinal gluconeogenesis(9,49); also, they represent potent
immune modulators, being involved in peripheral regulatory
T-cell generation(50) and in the regulation of pro-inflammatory
cytokine production(51). In parallel, the observed increase of
potential pro-inflammatory micro-organisms in the gut of
T2D patients, such as Enterobacteriaceae, Collinsella and
Streptococcus(32,39,43–46), could further contribute to raise the
host inflammatory level, supporting the evolution of insulin
resistance(52). Finally, the functional GM layout of T2D patients
we obtained by imputed metagenomics suggests additional
mechanisms involved in the GM contribution to the disease,
including the reduced production of the insulinogenic
arginine(34), and the increased production of alanine, a recog-
nised marker of higher energy intake and cholesterol level(35),
which could contribute to the loss of metabolic control in T2D.
Moreover, the higher potential for the production of tyrosine
metabolites could further boost pro-inflammatory stimuli in the
gut(36). Interestingly, the survey of GM in T2D patients allowed
us to find traces of functions related to immune escaping, such
as pathways involved in the metabolism of arachidonic acid and
polyketide sugar biosynthesis, further highlighting the ongoing
bloom of pro-inflammatory GM components in T2D(39).
However, the functional conclusions derived from imputed
metagenomics must be taken with caution until experimentally
confirmed by shotgun metagenomics.
In the subset of forty MADIAB participants – twenty-one
assigned to the Ma-Pi 2 diet and nineteen to the CTR diet – we
then explored the efficacy of the nutritional interventions in
supporting the recovery of a mutualistic GM configuration
in T2D patients. Primary and secondary outcomes were
re-analysed for this patient subset included in the gut micro-
biome study, confirming that the Ma-Pi 2 diet was associated
with a greater reduction in FBG and PPBG, total serum
cholesterol, CRP and IL-6 in T2D patients. According to gut
microbiome data, both Ma-Pi 2 and CTR diet were able to
modulate the GM dysbioses in T2D patients, supporting the
recovery of a healthy-like compositional structure and resulting
in an increased ecosystem diversity, which represents a strate-
gic feature for a healthy GM ecosystem(53). In addition, both
diets supported the recovery of a balanced health-promoting
community of fibrolytic SCFA producers in the gut of T2D
patients, by re-increasing the abundance of propionate and
butyrate producers (i.e. Bacteroides, Dorea, Faecalibacterium)
and consolidating a healthy-like abundance of Roseburia,
Lachnospira, Lachnospiraceae:Ruminococcus and Oscillospira.
Moreover, both dietary interventions resulted in the increase of
Akkermansia, a human mucus coloniser recently correlated to
an improved metabolic profile(54), providing the rationale for its
use in the prevention or treatment of obesity and associated
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Fig. 4. Impact of dietary interventions on the taxonomic structure of the core microbiota in type 2 diabetes (T2D) patients. Heat maps were calculated for both Ma-Pi 2
and control (CTR) diet, based on the log-ratio of the median genus abundance in T2D patients (T0 and T1 samples) and healthy controls. The colour code and
segment line reveal the deviation in terms of fold change from the median profile of healthy subjects ( ). T2D patients following the Ma-Pi 2 diet (n 21); T2D patients
following the CTR diet (n 19); healthy controls (n 13).
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the Ma-Pi 2 diet showed the potential to counteract the rise of
putative pro-inflammatory components (i.e. Collinsella and
Streptococcus) in the GM ecosystem of T2D patients. When we
sought associations between GM components and biochemical
parameters, significant trends were obtained only in the case of
the Ma-Pi 2 diet. Indeed, in Ma-Pi 2-treated subjects, the
abundance of Faecalibacterium was negatively associated with
FBG and, analogously, the abundance of Bacteroides and
Akkermansia showed an inverse association with total and
LDL-cholesterol. Conversely, Lachnospiraceae:Ruminococcus
was positively associated with FBG. These findings suggest that
these micro-organisms, the first increasing and the latter
decreasing in response to the Ma-Pi 2 diet, could represent
Ma-Pi 2-responding GM components associated with primary
and secondary study outcomes. Supporting our findings, the
negative association between Faecalibacterium and FBG
concentration had already been detected in a study exploring
the structural modulation of the GM in T2D subjects treated with
a Chinese herbal formula(55). Moreover, in a study carried out
in mice, Akkermansia muciniphila treatment has been
demonstrated to reverse high-fat diet-induced metabolic
disorders, including fat-mass gain, metabolic endotoxaemia,
adipose tissue inflammation and insulin resistance(54). On the
other hand, Lachnospiraceae:Ruminococcus has recently been
positively correlated with insulin resistance in obese women(56).
According to imputed metagenomics, only the Ma-Pi 2
diet resulted in a significant modulation of the functional
microbiome layout in T2D patients. In particular, the decrease
of several markers of functional GM dysbioses in T2D patients,
such as imbalances in alanine metabolism, arachidonic acid
metabolism and polyketide sugar biosynthesis, was observed.
Moreover, the Ma-Pi 2 diet favoured the reduction of
GM functions related to oxidative phosphorylation and























































































































Fig. 5. Impact of dietary components on the gut microbiota taxonomic structure. Cladogram obtained with the GraPhlAn tool, showing the family-level gut microbiota
profile of T1 samples from both intervention groups with a phylum-based colour code ( , Firmicutes; , Bacteroidetes; , Proteobacteria; , Actinobacteria;
, Verrucomicrobia; , Synergistetes). Families with relative abundance of at least 0·5% in at least two samples are plotted. Larger circles identify bacterial families
having a positive correlation with at least one dietary component; the names of these families are reported. Filled circles identify bacterial families that showed
significantly higher abundance in T1 samples of the Ma-Pi 2 diet group ( ) or the CTR diet group ( ). Bacterial family-food component correlations are indicated by
filled boxes in the external rings of the plot, referring to the list of dietary components. T2D patients following the Ma-Pi 2 diet (n 21); T2D patients following the CTR diet
(n 19).
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Fatty acids biosynthesis
Glycolysis/gluconeogenesis
D-Glutamine and D-Glutamate metabolism
D-Arginine and D-Ornithine metabolism
Pantothenate and CoA biosynthesis
Phenylpropanoid biosynthesis
Arachidonic acid metabolism
 Linolenic acid metabolism
Alanine, aspartate and glutamate metabolism











Fig. 6. Functional dysbioses of the gut microbiome in type 2 diabetes (T2D) patients. Metabolic pathways were superimposed on the principal component analysis plot
based on Euclidean distances, and the pathways responsible for the separation are shown. , Healthy controls (n 13); , T2D patients (n 40). Sphere width is
proportional to the mean relative abundance of the function across all samples. The two components explain 14·0 and 9·2% of the variance, respectively. P= 0·03;
permutation test with pseudo F ratios. , , Centroids for each group with indication of standard errors on each coordinate axis.
Taurine and hypotaurine metabolism
Purine metabolism
Valine, leucine and isoleucine metabolism
Cysteine and methionine metabolism
Biosynthesis of unsaturated fatty acids
Alanine, aspartate and glutamate metabolism




















Fig. 7. Impact of Ma-Pi 2 dietary intervention on the functional configuration of the gut microbiome in type 2 diabetes (T2D) patients. Metabolic pathways were superimposed on
the principal component analysis plot based on Euclidean distances in T2D patients before (T0, ) and after (T1, ) the Ma-Pi 2 diet (n 21). The two components explain 22·3
and 14·9% of the variance, respectively. P=0·007; permutation test with pseudo F ratios. , , Centroids for each group with indication of standard errors on each
coordinate axis.
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an ecological advantage for Enterobacteriaceae in an inflamed
gut(39), whereas glycosphingolipids are powerful bacterial
modulators of the host inflammatory response(40). Thus, the
reduction in abundance of these pathways further suggests
the potential of Ma-Pi 2 diet to counteract the ongoing bloom
of pro-inflammatory pathobionts in T2D. Finally, the Ma-Pi 2
diet favoured the increase of GM functions involved in the
biosynthesis of unsaturated fatty acids and essential amino
acids, showing an added potential to promote the recovery of
metabolic control and a balanced nutritional status in T2D
patients.
In conclusion, both Ma-Pi 2 and CTR diets showed the
potential to support the recovery of GM-host mutualism in T2D
patients, favouring the restoration of fibrolytic SCFA-producing
GM components, thus promoting metabolic control of T2D
patients. Differently from the CTR diet, the Ma-Pi 2 diet was
effective in counteracting the rise of possible pro-inflammatory
micro-organisms in T2D patients. This suggests that the Ma-Pi 2
diet may have the potential to reduce GM-dependent
pro-inflammatory stimuli in the gut that, increasing chronic
inflammation, can lead to insulin resistance in T2D(57). Even if
direct causation still needs to be proved, and this conclusion
must be taken with adequate caution, this peculiar property
shown by the Ma-Pi 2 diet could partly explain the greater
improvements in metabolic control following Ma-Pi 2 dietary
intervention compared with the CTR diet(21).
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